Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

29.98 -3.25 (-9.80%)
Streaming Delayed Price Updated: 3:58 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
From Vericel Corporation
Via GlobeNewswire
MediWound Revenue Jumps 43% in Q2
Via The Motley Fool
Vericel Corp (NASDAQ:VCEL): A High-Growth Stock with a Promising Technical Setup
Vericel Corp (VCEL) is a high-growth biotech stock with strong fundamentals and a promising technical setup, making it a potential breakout candidate for investors. 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Where Vericel Stands With Analysts
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Vericel
 
Via Benzinga
Vericel Q2 Revenue Jumps 20%
Via The Motley Fool
Topics Intellectual Property
Vericel Corp (NASDAQ: VCEL) Posts Mixed Q2 2025 Results with Revenue Miss and EPS Beat
Vericel Corp (VCEL) posted mixed Q2 2025 results with revenue missing estimates but EPS beating expectations. Shares fell 6.5% pre-market despite strong MACI growth and margin expansion. 
Via Chartmill
Vericel Reports Second Quarter 2025 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
From Vericel Corporation
Via GlobeNewswire
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
 
Via Benzinga
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong growth fundamentals and a technical breakout pattern, making it a stock to watch in the biotech sector. 
Via Chartmill
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
From Vericel Corporation
Via GlobeNewswire
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong revenue and earnings growth, backed by a solid balance sheet and a promising technical breakout pattern. 
Via Chartmill
What Analysts Are Saying About Vericel Stock
 
Via Benzinga
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with a Technical Setup
VERICEL CORP (NASDAQ:VCEL) shows strong growth potential with solid profitability and a promising technical setup, making it a stock worth watching. 
Via Chartmill
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at Multiple Upcoming Investor Conferences
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
From Vericel Corporation
Via GlobeNewswire
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.